AU2013263188A1 - Therapeutic uses of fibroblast growth factor 21 proteins - Google Patents

Therapeutic uses of fibroblast growth factor 21 proteins Download PDF

Info

Publication number
AU2013263188A1
AU2013263188A1 AU2013263188A AU2013263188A AU2013263188A1 AU 2013263188 A1 AU2013263188 A1 AU 2013263188A1 AU 2013263188 A AU2013263188 A AU 2013263188A AU 2013263188 A AU2013263188 A AU 2013263188A AU 2013263188 A1 AU2013263188 A1 AU 2013263188A1
Authority
AU
Australia
Prior art keywords
pro
leu
seq
bone
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013263188A
Other languages
English (en)
Inventor
Armando Rafael IRIZARRY ROVIRA
Yanfei Linda Ma
Vincent Louis REYNOLDS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013263188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013263188A1 publication Critical patent/AU2013263188A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013263188A 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins Abandoned AU2013263188A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US61/646,974 2012-05-15
US201361786939P 2013-03-15 2013-03-15
US61/786,939 2013-03-15
PCT/US2013/040275 WO2013173158A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Publications (1)

Publication Number Publication Date
AU2013263188A1 true AU2013263188A1 (en) 2014-10-16

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013263188A Abandoned AU2013263188A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Country Status (21)

Country Link
US (1) US20150141335A1 (enExample)
EP (1) EP2852398A1 (enExample)
JP (1) JP2015522539A (enExample)
KR (1) KR20150002801A (enExample)
CN (1) CN104302311A (enExample)
AU (1) AU2013263188A1 (enExample)
BR (1) BR112014028413A2 (enExample)
CA (1) CA2869320A1 (enExample)
CL (1) CL2014002846A1 (enExample)
CO (1) CO7131381A2 (enExample)
EA (1) EA201491856A1 (enExample)
HK (1) HK1202800A1 (enExample)
IL (1) IL235482A0 (enExample)
MA (1) MA37506B1 (enExample)
MX (1) MX2014013913A (enExample)
PE (1) PE20142432A1 (enExample)
PH (1) PH12014502537A1 (enExample)
SG (1) SG11201407655TA (enExample)
TN (1) TN2014000409A1 (enExample)
WO (1) WO2013173158A1 (enExample)
ZA (1) ZA201407532B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016039339A1 (ja) * 2014-09-08 2016-03-17 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
AU2020230668B2 (en) 2019-03-05 2025-05-29 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
BR112014028413A2 (pt) 2017-11-07
US20150141335A1 (en) 2015-05-21
PH12014502537A1 (en) 2015-01-21
MX2014013913A (es) 2015-02-17
JP2015522539A (ja) 2015-08-06
IL235482A0 (en) 2014-12-31
WO2013173158A1 (en) 2013-11-21
HK1202800A1 (en) 2015-10-09
MA37506A1 (fr) 2016-01-29
ZA201407532B (en) 2016-05-25
CN104302311A (zh) 2015-01-21
CA2869320A1 (en) 2013-11-21
CO7131381A2 (es) 2014-12-01
EA201491856A1 (ru) 2015-03-31
MA37506B1 (fr) 2017-03-31
KR20150002801A (ko) 2015-01-07
PE20142432A1 (es) 2015-01-22
CL2014002846A1 (es) 2015-01-30
EP2852398A1 (en) 2015-04-01
TN2014000409A1 (en) 2015-12-21
SG11201407655TA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
EP2852398A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
Estell et al. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Iwata et al. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia
Amizuka et al. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation.
Van Bezooijen et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
Ballock et al. Physiology and pathophysiology of the growth plate
Zemel et al. Agouti regulation of intracellular calcium: role in the insulin resistance of viable yellow mice.
Makino et al. Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide
Sabir et al. The evolving therapeutic landscape of genetic skeletal disorders
Kim et al. The role of nacreous factors in preventing osteoporotic bone loss through both osteoblast activation and osteoclast inactivation
McGregor et al. Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling
Yang et al. A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice
Robling et al. Anabolic and catabolic regimens of human parathyroid hormone 1–34 elicit bone-and envelope-specific attenuation of skeletal effects in Sost-deficient mice
JP2013032385A (ja) 新しい骨量増加薬
Fahmy-Garcia et al. Follistatin effects in migration, vascularization, and osteogenesis in vitro and bone repair in vivo
Calvi et al. The PTH/PTHrP receptor in Jansen’s metaphyseal chondrodysplasia
Yavropoulou et al. Incretins and bone: evolving concepts in nutrient-dependent regulation of bone turnover
Tudpor et al. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio
Karapl PTHrP Novel Roles in Skeletal Biology.
Luo et al. Progesterone upregulates TGF-b isoforms (b1, b2, and b3) expression in normal human osteoblast-like cells
Conen et al. The transcriptional cofactor Lbh regulates angiogenesis and endochondral bone formation during fetal bone development
Villa et al. Effects of amylin on human osteoblast-like cells
Zhao et al. CCN1/Cyr61 is required in osteoblasts for responsiveness to the anabolic activity of PTH
Bessa-Andrês et al. Silencing P2Y12 and P2Y13 receptors rehabilitates the ADP-induced P2Y1-mediated osteogenic commitment of post-menopausal mesenchymal stromal cells
Karaplis et al. Role of PTHrP and PTH-1 receptor in endochondral bone development

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period